COMMUNIQUÉS West-GlobeNewswire

GBT Appoints Wendy L. Yarno to Board of Directors
22/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has [...]
Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics
22/12/2017
Company to focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations WALTHAM, Mass., REHOVOT, Israel, and SAN DIEGO, Dec. 22, 2017 (GLOBE [...]
Tauriga Sciences, Inc. Extinguishes its Largest Remaining Balance Sheet Liability for One Time Cash Payment of $15,000 and One Time Issuance of 5,000,000 Restricted Shares; Liability Dated Back to the Years 2010/2011 and Totaled $177,883.71
22/12/2017
NEW YORK, NY, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building business through the development, distribution, and licensing of proprietary [...]
Achaogen Announces New Employment Inducement Grants
22/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]
Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
22/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that it will host an investor event to discuss expected corporate and product milestones in [...]
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
22/12/2017
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the active moiety [...]
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
22/12/2017
PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ: AGRX ), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response [...]
RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
22/12/2017
YELIVA ® , a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma Cholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there [...]
Avivagen Inc. Announces the Granting of Options
22/12/2017
OTTAWA, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSX-V: VIV ) (OTC Pink:CHEXF) (“ Avivagen ” or the “ Company ”), a life sciences innovation company with a series of patent protected products that support and [...]
Saniona AB: Notice of extraordinary shareholders' meeting in Saniona AB
22/12/2017
PRESS RELEASE December 22, 2017 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail . The shareholders in [...]
Serendipity Ixora proposes distribution of its Xbrane shares to its shareholders, after which Serendipity Group becomes the largest shareholder in Xbrane if the distribution is executed
22/12/2017
Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") informs that the Company's largest shareholder Serendipity Ixora AB ("Serendipity Ixora"), intends to distribute all its shares in Xbrane [...]
Xbrane Biopharma largest shareholder Serendipity Group issues a credit facility of SEK 50 million to the company
22/12/2017
Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today got issued a credit facility from Serendipity Group AB ("Serendipity Group") of SEK 50 million (the "Credit Facility"). The [...]
Saniona AB: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the Board of Directors
22/12/2017
PRESS RELEASE December 22, 2017 Saniona, a leading biotech company in the field of ion channels, today announced that its Nomination Committee comprised of Søren Skjærbæk appointed by Jørgen Drejer, John Haurum [...]
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
22/12/2017
Priority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key secondary endpoints including [...]
Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO
22/12/2017
SHANGHAI, China, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced George Lin, a seasoned investment banker in the U.S. and Asia, joins Hua [...]
DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
22/12/2017
MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V: DMA ) (OTCQB:DMCAF) (the “ Company ”), today announced that at its Annual General and Special Meeting (the “ Meeting ”) of shareholders [...]
La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)
22/12/2017
Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La [...]
Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit
21/12/2017
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit ( [...]
Akers Biosciences Announces Closing of $6,900,000 Public Offering
21/12/2017
THOROFARE, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or “Akers Bio”), a developer of rapid health information technologies, today announces the closing [...]

Pages